Hepion Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

HEPA$0.07-17.7%Stored close · as of Jul 8, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31,
	2025	2024
Assets
Current assets:
Cash	$1,828,062	$406,408
Prepaid expenses	1,241,890	1,207,329
Total current assets	3,069,952	1,613,737
Total assets	$3,069,952	$1,613,737
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$167,810	$220,202
Accrued expenses	77,507	23,684
Notes payable, current	54,066	2,900,000
Total current liabilities	299,383	3,143,886
Derivative financial instruments—warrants	103,022	333,189
Total liabilities	402,405	3,477,075
Commitments and contingencies (see Note 12)	-	-
Stockholders’ equity:
Series A convertible preferred stock, stated value $10 per share, 85,581 shares issued and outstanding at December 31, 2025 and 2024, respectively.	855,808	855,808
Series C convertible preferred stock, stated value $1,000 per share, 1,688 shares issued and outstanding at December 31, 2025 and 2024.	839,320	839,320
Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 11,620,317 and 139,168 shares issued and outstanding at December 31, 2025 and 2024, respectively.	1,162	14
Additional paid-in capital	247,060,568	234,252,981
Accumulated other comprehensive income (loss)	8,345	8,345
Accumulated deficit	(246,097,656)	(237,819,806)
Total stockholders’ equity	2,667,547	(1,863,338)
Total liabilities and stockholders’ equity	$3,069,952	$1,613,737

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.